{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:54:33Z","timestamp":1769201673301,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2013-CoG 614739-A_HERO"],"award-info":[{"award-number":["ERC-2013-CoG 614739-A_HERO"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.coph.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T14:09:29Z","timestamp":1533132569000},"page":"27-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6423-3183","authenticated-orcid":false,"given":"Gordana","family":"Panic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.06.004_bib0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.4155\/fmc.15.16","article-title":"Praziquantel: do we need another antischistosomal treatment?","volume":"7","author":"Obe","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0010","unstructured":"World Health Organisation: WHO urges increased access to praziquantel as schistosomiasis treatment coverage improves. Geneva: WHO; 2016."},{"key":"10.1016\/j.coph.2018.06.004_bib0015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jac\/dkt491","article-title":"The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer)","volume":"69","author":"Olliaro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0020","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","article-title":"Susceptibility or resistance of praziquantel in human schistosomiasis: a review","volume":"111","author":"Wang","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.coph.2018.06.004_bib0025","doi-asserted-by":"crossref","first-page":"20130434","DOI":"10.1098\/rstb.2013.0434","article-title":"The contribution of mass drug administration to global health: past, present and future","volume":"369","author":"Webster","year":"2014","journal-title":"Phil Trans R Soc B"},{"key":"10.1016\/j.coph.2018.06.004_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40249-017-0286-2","article-title":"Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?","volume":"6","author":"Bergquist","year":"2017","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.coph.2018.06.004_bib0035","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4155\/fmc.15.9","article-title":"Something old, something new: is praziquantel enough for schistosomiasis control?","volume":"7","author":"Secor","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_sbref0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4155\/fmc-2017-0112","article-title":"Antischistosomal agents: state of art and perspectives","volume":"10","author":"Lago","year":"2017","journal-title":"Future Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0001-706X(03)00033-0","article-title":"Administration of praziquantel to pregnant and lactating women","volume":"86","author":"Olds","year":"2003","journal-title":"Acta Trop"},{"key":"10.1016\/j.coph.2018.06.004_bib0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1086\/649924","article-title":"Effects of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, Uganda: A randomized controlled trial","volume":"50","author":"Ndibazza","year":"2010","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.coph.2018.06.004_bib0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S1473-3099(15)00345-X","article-title":"Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Olveda","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coph.2018.06.004_sbref0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2471\/BLT.17.198879","article-title":"Praziquantel for the treatment of schistosomiasis during human pregnancy","volume":"96","author":"Friedman","year":"2018","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.coph.2018.06.004_bib0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13071-016-1958-7","article-title":"Efficacy and safety of praziquantel 40 mg\/kg in preschool-aged and school-aged children: a meta-analysis","volume":"10","author":"Zwang","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.coph.2018.06.004_sbref0070","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2214-109X(17)30187-0","article-title":"Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial","volume":"5","author":"Coulibaly","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10.1016\/j.coph.2018.06.004_bib0075","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12916-018-1066-y","article-title":"Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial","volume":"16","author":"Coulibaly","year":"2018","journal-title":"BMC Medicine"},{"key":"10.1016\/j.coph.2018.06.004_bib0080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02253-17","article-title":"Pharmacokinetics of praziquantel in Schistosoma mansoni and Schistosoma haematobium infected school- and preschool-aged children","volume":"62","author":"Kova\u010d","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0085","doi-asserted-by":"crossref","first-page":"e0005942","DOI":"10.1371\/journal.pntd.0005942","article-title":"Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model","volume":"11","author":"Abla","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coph.2018.06.004_bib0090","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1128\/AAC.02741-14","article-title":"Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni","volume":"58","author":"Meister","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s13071-017-2293-3","article-title":"In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium","volume":"10","author":"Kova\u010d","year":"2017","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.coph.2018.06.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00227-16","article-title":"Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy","volume":"7","author":"Bustinduy","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.coph.2018.06.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-018-9601-1","article-title":"Extrapolation of praziquantel pharmacokinetics to a pediatric population \u2013 a cautionary tale","author":"Bonate","year":"2018","journal-title":"J Pharmacokinet Dyn"},{"key":"10.1016\/j.coph.2018.06.004_sbref0110","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13071-018-2739-2","article-title":"Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome","volume":"11","author":"Schneeberger","year":"2018","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.coph.2018.06.004_bib0115","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1021\/acs.jproteome.7b00910","article-title":"Characterizing the biochemical response to Schistosoma mansoni infection and treatment with praziquantel in pre-school and school-aged children","volume":"17","author":"Panic","year":"2018","journal-title":"J Proteome Res"},{"key":"10.1016\/j.coph.2018.06.004_bib0120","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1039\/c0mb00262c","article-title":"Metabonomic investigation of human Schistosoma mansoni infection","volume":"7","author":"Balog","year":"2011","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.coph.2018.06.004_bib0125","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0020-7519(02)00194-7","article-title":"Artemisinin: mechanisms of action, resistance and toxicity","volume":"32","author":"Meshnick","year":"2002","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.coph.2018.06.004_bib0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpara.2016.10.005","article-title":"Schistosoma hemozoin and its possible roles","volume":"47","author":"Xiao","year":"2017","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.coph.2018.06.004_bib0135","first-page":"3531","article-title":"Antimalarials in the treatment of schistosomiasis","volume":"18","author":"Keiser","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.coph.2018.06.004_bib0140","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02779","article-title":"Identification of an antimalarial synthetic trioxolane drug development candidate","volume":"430","author":"Vennerstrom","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.coph.2018.06.004_bib0145","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/AAC.05371-11","article-title":"In vivo activity of aryl ozonides against Schistosoma species","volume":"56","author":"Keiser","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.actatropica.2014.12.005","article-title":"Efficacy of SynriamTM, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni","volume":"143","author":"Mossallam","year":"2015","journal-title":"Acta Trop"},{"key":"10.1016\/j.coph.2018.06.004_bib0155","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1128\/AAC.01537-06","article-title":"In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species","volume":"51","author":"Xiao","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0160","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s00436-011-2765-x","article-title":"Effectiveness of synthetic trioxolane OZ78 against Schistosoma japonicum in mice and rabbits","volume":"110","author":"Xiao","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.coph.2018.06.004_bib0165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00436-010-2084-7","article-title":"Schistosoma japonicum-infected hamsters (Mesocricetus auratus) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds","volume":"108","author":"Xiao","year":"2011","journal-title":"Parasitol Res"},{"key":"10.1016\/j.coph.2018.06.004_bib0170","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s00436-014-3988-4","article-title":"Effect of ozonide OZ418 against Schistosoma japonicum harbored in mice","volume":"113","author":"Xue","year":"2014","journal-title":"Parasitol Res"},{"key":"10.1016\/j.coph.2018.06.004_sbref0175","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1128\/AAC.02394-15","article-title":"Pharmacokinetics of the antischistosomal lead ozonide OZ418 in uninfected mice determined by liquid chromatography-tandem mass spectrometry","volume":"60","author":"Leonidova","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0180","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2174\/1389557511313040003","article-title":"The evolution of drugs on Schistosoma treatment: looking to the past to improve the future","volume":"13","author":"da Rocha Pitta","year":"2013","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0185","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/jac\/dkv016","article-title":"Aryl hydantoin Ro 13-3978, a broad-spectrum antischistosomal","volume":"70","author":"Keiser","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0190","first-page":"261","article-title":"3-Arylhydantoine, eine Substanzklasse mit schistosomizider Wirkung","volume":"19","author":"Link","year":"1984","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0195","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01142-17","article-title":"Immunohistochemical investigations of treatment with Ro 13-3978, praziquantel, oxamniquine and mefloquine in Schistosoma mansoni-infected mice","volume":"61","author":"Panic","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0200","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1021\/acs.jmedchem.6b01410","article-title":"Revisiting the SAR of the antischistosomal aryl hydantoin (Ro 13-3978)","volume":"59","author":"Wang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0205","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4269\/ajtmh.14-0029","article-title":"Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978","volume":"90","author":"Wang","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coph.2018.06.004_bib0210","series-title":"International Congress for Tropical Medicine and Malaria, 11. Calgary, Canada","article-title":"9-Acridanone-hydrazones, a novel class of broad-spectrum schistosomal agents","author":"Stohler","year":"1984"},{"key":"10.1016\/j.coph.2018.06.004_bib0215","first-page":"975","article-title":"Study of the efficacy of the new antischistosomal drug 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone against an Egyptian strain of Schistosoma mansoni in mice","volume":"47","author":"Metwally","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.coph.2018.06.004_bib0220","first-page":"57","article-title":"Efficacy of praziquantel and Ro 15-5458, a 9-acridanone-hydrazone derivative, against Schistosoma haematobium","volume":"53","author":"Guirguis","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.coph.2018.06.004_bib0225","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00436-009-1546-2","article-title":"Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use","volume":"105","author":"Abdul-Ghani","year":"2009","journal-title":"Parasitol Res"},{"key":"10.1016\/j.coph.2018.06.004_bib0230","article-title":"recent insights on the medicinal chemistry of metal-based compounds: hints for the successful drug design","author":"Hernandes","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0235","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.ccr.2008.12.003","article-title":"Gold complexes as potential anti-parasitic agents","volume":"253","author":"Navarro","year":"2009","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.coph.2018.06.004_bib0240","doi-asserted-by":"crossref","first-page":"821","DOI":"10.4155\/fmc.15.22","article-title":"Toward organometallic antischistosomal drug candidates","volume":"7","author":"Hess","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.coph.2018.06.004_bib0245","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1126\/science.1243106","article-title":"Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites","volume":"342","author":"Valentim","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coph.2018.06.004_bib0250","series-title":"Sixty Sixth Annual Meeting. American Journal of Tropical Medicine and Hygiene","article-title":"Why does oxamniquine kill Schistosoma mansoni but not S. haematobium or S. japonicum?","author":"Rugel","year":"2017"},{"key":"10.1016\/j.coph.2018.06.004_sbref0255","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1021\/acsinfecdis.7b00054","article-title":"Ferrocenyl, ruthenocenyl, and benzyl oxamniquine derivatives with cross-species activity against Schistosoma mansoni and Schistosoma haematobium","volume":"3","author":"Hess","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.coph.2018.06.004_bib0260","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/JRS-2008-0440","article-title":"A review of the safety of niclosamide, pyrantel, triclabendazole and oxamniquine","volume":"20","author":"Ofori-Adjei","year":"2008","journal-title":"Int J Risk Saf Med"},{"key":"10.1016\/j.coph.2018.06.004_sbref0265","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1128\/AAC.00778-16","article-title":"Discovery of antischistosomal drug leads based on tetraazamacrocyclic derivatives and their metal complexes","volume":"60","author":"Khan","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0270","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.01304-08","article-title":"Synthesis and antimalarial activities of cyclen 4-aminoquinoline analogs","volume":"53","author":"Khan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.coph.2018.06.004_bib0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/cmdc.200700127","article-title":"Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial","volume":"3","author":"Dive","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.coph.2018.06.004_bib0280","series-title":"Medicinal Organometallic Chemistry","first-page":"81","article-title":"Ferrocene functionalized endocrine modulators as anticancer agents","author":"Hillard","year":"2010"},{"key":"10.1016\/j.coph.2018.06.004_bib0285","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4269\/ajtmh.14-0675","article-title":"Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions","volume":"92","author":"Barakat","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.coph.2018.06.004_bib0290","doi-asserted-by":"crossref","first-page":"e0005008","DOI":"10.1371\/journal.pntd.0005008","article-title":"Efficacy and safety of moxidectin, Synriam, Synriam-praziquantel versus praziquantel against Schistosoma haematobium and S. mansoni infections: a randomized, exploratory phase 2 trial","volume":"10","author":"Barda","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.coph.2018.06.004_bib0295","first-page":"16","article-title":"New developments in anti-malarial target candidate and product profiles","author":"Burrows","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/j.coph.2018.06.004_bib0300","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.coph.2018.06.004_bib0305","unstructured":"DNDi: Flubendazole Macrofilaricide. 2013."}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217301583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489217301583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:48:41Z","timestamp":1761461321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489217301583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":61,"alternative-id":["S1471489217301583"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.06.004","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}